Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease
暂无分享,去创建一个
[1] T. Jones,et al. 2D and 3D imaging of small animals and the human radial artery with a high resolution detector for PET , 1992 .
[2] Antoine Geissbühler,et al. 2D And 3D Imaging Of Small Animals And The Human Radial Artery With A High Resolution Detector For PET , 1990, 1990 IEEE Nuclear Science Symposium Conference Record.
[3] E. Ruzický,et al. Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea. , 1992, Stereotactic and functional neurosurgery.
[4] G. Sedvall,et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.
[5] T. Sharp,et al. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat , 1998, Psychopharmacology.
[6] S. Stone-Elander,et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.
[7] T. Reader,et al. Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies , 1997, Neurochemistry International.
[8] P Riederer,et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[9] R. M. Murray,et al. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia , 1992, The Lancet.
[10] J. Arnt,et al. Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence , 1998, Neuropsychopharmacology.
[11] C D Marsden,et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.
[12] M. Peschanski,et al. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease , 1995, Neuroscience.
[13] E. Richfield,et al. Heterogeneous dopamine receptor changes in early and late Huntington's disease , 1991, Neuroscience Letters.
[14] L. Bäckman,et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.
[15] W. Martin,et al. Cortical glucose metabolism in Huntington's disease , 1992, Neurology.
[16] S. Folstein,et al. Nigral dopamine type-1 receptors are reduced in Huntington's disease: A postmortem autoradiographic study using [3H]SCH 23390 and correlation with [3H]forskolin binding , 1990, Experimental Neurology.
[17] C. Markham,et al. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease , 1984, Annals of neurology.
[18] M. Hayden,et al. Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.
[19] S B Dunnett,et al. Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. , 1995, Neuroreport.
[20] D. Brooks,et al. Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.
[21] C. Olanow,et al. Neural transplantation as a therapy for Parkinson's disease. , 1997, Advances in neurology.
[22] W. Galpern,et al. In vivo PET Imaging in rat of dopamine terminals reveals functional neural transplants , 1998, Annals of neurology.
[23] I. Creese,et al. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. , 1997, The Journal of pharmacology and experimental therapeutics.
[24] Joseph B. Martin. Huntington's disease , 1984, Neurology.
[25] S. Jacques,et al. Safety of Intrastriatal Neurotransplantation for Huntington's Disease Patients , 1998, Experimental Neurology.
[26] J. Nobrega,et al. Regional brain changes in [3H]SCH 23390 binding to dopamine D1 receptors after long-term haloperidol treatment: lack of correspondence with the development of vacuous chewing movements , 1998, Behavioural Brain Research.
[27] B. Lipska,et al. D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment , 1992, Brain Research.
[28] D. Eidelberg,et al. [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.
[29] F. Ostrosky-solis,et al. Fetal striatal homotransplantation for Huntington's disease: first two case reports. , 1995, Neurological research.
[30] Adriaan A. Lammertsma,et al. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease , 1996, Journal of Neuroscience Methods.
[31] R. Myers,et al. Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography , 1992, Synapse.
[32] P Boesiger,et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.
[33] S. Dunnett,et al. The problem of antipsychotic treatment for functional imaging in Huntington's disease: receptor binding, gene expression and locomotor activity after sub-chronic administration and wash-out of haloperidol in the rat , 2000, Brain Research.
[34] O. Lindvall. Prospects of transplantation in human neurodegenerative diseases , 1991, Trends in Neurosciences.
[35] O. Lindvall,et al. Core assessment program for intracerebral transplantation in Huntington's disease (CAPIT‐HD) , 1996, Movement disorders : official journal of the Movement Disorder Society.
[36] I. Creese,et al. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment , 1997, Neuroscience.
[37] J C Mazziotta,et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. , 1992, Archives of neurology.
[38] M. Patterson,et al. Fetal Transplantation for Huntington’s Disease: Clinical Studies , 1998 .
[39] D. Brooks,et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. , 1995, Brain : a journal of neurology.
[40] M. Rossor,et al. Dopamine D-1 and D-2 receptors in Huntington's disease. , 1983, European journal of pharmacology.
[41] M. Peschanski,et al. Chapter 35 Prospectives for cell and gene therapy in Huntington's disease , 1998 .
[42] V. Klimek,et al. Chronic treatment with antidepressants decreases the number of [3H]SCH 23390 binding sites in the rat striatum and limbic system. , 1987, European journal of pharmacology.
[43] E. Bird,et al. Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia , 1988, Synapse.
[44] Guy V. Sawle,et al. The role of positron emission tomography in the assessment of human neurotransplantation , 1993, Trends in Neurosciences.
[45] G. Sedvall,et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.
[46] R Myers,et al. The effects of donor stage on the survival and function of embryonic striatal grafts in the adult rat brain II. Correlation between positron emission tomography and reaching behaviour , 1997, Neuroscience.
[47] C. Halldin,et al. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. , 1997, Archives of general psychiatry.
[48] P. Sanberg,et al. Fetal-Tissue Transplantation for Huntington’s Disease: Preclinical Studies , 1998 .
[49] K. Shannon,et al. Neural Transplantation for Huntington's Disease: Experimental Rationale and Recommendations for Clinical Trials , 1996, Cell transplantation.
[50] C. Olanow,et al. Fetal nigral transplantation as a therapy for Parkinson's disease , 1996, Trends in Neurosciences.
[51] S. Kapur,et al. A new framework for investigating antipsychotic action in humans: lessons from PET imaging , 1998, Molecular Psychiatry.
[52] L. Philpott,et al. Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. , 1997, Cell transplantation.
[53] Y. Agid,et al. Are cognitive changes the first symptoms of Huntington’s disease? A study of gene carriers , 1998, Journal of neurology, neurosurgery, and psychiatry.
[54] R. Ridley,et al. Functional integration of striatal allografts in a primate model of Huntington's disease , 1998, Nature Medicine.
[55] O. Lindvall. Neural transplantation: a hope for patients with Parkinson's disease , 1997, Neuroreport.
[56] Björn Gustavii,et al. Short‐ and long‐term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease , 1997, Annals of neurology.
[57] A Weindl,et al. Central motor processing in Huntington's disease. A PET study. , 1997, Brain : a journal of neurology.
[58] P. Remy,et al. MRI-Stereotactical Approach for Neural Grafting in Basal Ganglia Disorders , 1998, Experimental Neurology.